Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Investor in connection with acquisition of shares in Mölnlycke Health Care
Mandate

Vinge advises Investor in connection with acquisition of shares in Mölnlycke Health Care

August 26, 2010

Vinge is advising Investor AB (publ) in connection with Investor’s agreement with Morgan Stanley Principal Investments to acquire Morgan Stanley’s 34 per cent equity stake in Mölnlycke Health Care Group AB. The purchase price amounts to EUR 510 million and following the transaction Investor will hold a 96 per cent equity stake. The remaining shares will be owned by Mölnlycke’s management and board.

Mölnlycke is a world leading manufacturer and provider of single-use surgical and wound care products and services, primarily for the professional healthcare sector. Investor together with Morgan Stanley originally invested in Mölnlycke in 2007.

Vinge’s team advising Investor consists of Ola Sandersson, Pontus Enquist, Dain Nevonen and Fredrik von der Esch. Johan Karlsson and Peter Alstegren are providing competiton law advice. Hans Wibom is the client relationship partner.

Related

Vinge advises Revivo Group on the acquisition of IdeaPaint

 Revivo Group is continuing its expansion in Finland through the acquisition of IdeaPaint Oy, a Tampere-based company specialising in industrial surface treatment.
September 21, 2026

Vinge advises Fortinova Fastigheter AB (publ) on its first SEK 200 million green bond issue

 Vinge has advised Fortinova Fastigheter AB (publ) (“Fortinova”) on the company’s first issue of senior unsecured green bonds in an aggregate principal amount of SEK 200 million, under a framework of up to SEK 600 million. Nordea, acted as sole bookrunner in connection with the bond issue.
September 18, 2026

Vinge advises Morrow Bank AB (publ) in connection with the bank’s sale of parts of MedMera Bank and the sale of NPL portfolios

 Vinge has advised Morrow Bank AB (publ) in connection with the divestment of parts of MedMera Bank’s operations to a leading global credit investment firm. The divestment is structured as a sale of shares and priced at a premium of approximately SEK 90 million above equity value as per the completion date. The transaction includes parts of MedMera’s banking operations such as IT infrastructure, organisation and management, whilst Morrow Bank retains MedMera’s performing loans, deposits, customers, the MedMera brand, the Coop partnership agreement as well as key personnel.
September 15, 2026